Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

AN Gordon, JT Fleagle, D Guthrie, DE Parkin… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD)
and topotecan in patients with epithelial ovarian carcinoma that recurred after or didn't …

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

DG Mutch, M Orlando, T Goss, MG Teneriello… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Ovarian cancer (OC) patients experiencing progressive disease (PD) within 6
months of platinum-based therapy in the primary setting are considered platinum resistant …

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and …

AN Gordon, M Tonda, S Sun, W Rackoff - Gynecologic oncology, 2004 - Elsevier
OBJECTIVE: Provide long-term follow-up data for women treated in a randomized
multicenter study of pegylated liposomal doxorubicin compared with topotecan. METHODS …

Role of pegylated liposomal doxorubicin in ovarian cancer

JT Thigpen, CA Aghajanian, DS Alberts… - Gynecologic …, 2005 - Elsevier
OBJECTIVES: Safe, effective treatments are needed for relapsed ovarian cancer. Goals
include improving symptoms, enhancing quality of life, and prolonging survival. The plethora …

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results …

AN Gordon, N Finkler, RP Edwards… - International Journal of …, 2005 - ijgc.bmj.com
The aim of this single-arm, phase II study was to estimate the tumor response rate and safety
profile of erlotinib HCl (erlotinib, Tarceva™, OSI-774) monotherapy in patients with …

[PDF][PDF] Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or …

C Lhommé, F Joly, JL Walker, AA Lissoni… - Clinical …, 2002 - academia.edu
Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared
With Paclitaxel and Carboplatin Alone i Page 1 Phase III Study of Valspodar (PSC 833) …

[HTML][HTML] Glucagon lowers glycemia when β cells are active

ME Capozzi, JB Wait, J Koech, AN Gordon, RW Coch… - JCI insight, 2019 - ncbi.nlm.nih.gov
Glucagon and insulin are commonly believed to have counteracting effects on blood
glucose levels. However, recent studies have demonstrated that glucagon has a physiologic …

Validation of referral guidelines for women with pelvic masses

SS Im, AN Gordon, BM Buttin, CA Leath III… - Obstetrics & …, 2005 - journals.lww.com
OBJECTIVE: Guidelines for referring women with pelvic masses suspicious for ovarian
cancers to gynecologic oncologists have been published jointly by Society of Gynecologic …

Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non–small-cell lung cancer, ovarian cancer, and non-Hodgkin's …

HA Burris III, CP Belani, PA Kaufman… - Journal of oncology …, 2010 - ascopubs.org
Purpose: To compare data on severe (grade 4) neutropenia duration and febrile
neutropenia incidence in patients receiving chemotherapy with pegfilgrastim administered …

Lesions Caused by Cardiovascular Flukes (Digenea: Spirorchidae) in Stranded Green Turtles (Chelonia mydas)

AN Gordon, WR Kelly, TH Cribb - Veterinary Pathology, 1998 - journals.sagepub.com
Evidence of infection with spirorchid flukes (Digenea: Spirorchidae) was sought at necropsy
of 96 stranded green turtles, Chelonia mydas, that were examined during the course of a …